Medigene AG (ETR:MDG1 – Get Free Report) was down 1.7% on Friday . The stock traded as low as €1.59 ($1.68) and last traded at €1.66 ($1.75). Approximately 5,019 shares traded hands during trading, a decline of 98% from the average daily volume of 306,207 shares. The stock had previously closed at €1.69 ($1.78).
Medigene Price Performance
The company has a debt-to-equity ratio of 12.94, a current ratio of 2.39 and a quick ratio of 5.85. The firm’s 50-day moving average is €1.89 and its two-hundred day moving average is €1.49. The company has a market cap of $24.50 million, a P/E ratio of -1.37, a PEG ratio of 7.12 and a beta of 0.84.
Medigene Company Profile
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Further Reading
- Five stocks we like better than Medigene
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- What is the S&P 500 and How It is Distinct from Other Indexes
- Top-Performing Non-Leveraged ETFs This Year
- How to Invest in the Best Canadian Stocks
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.
